← Leaderboards
Travis Dunckley
Iluminos Therapeutics, Llc
$1,711,768
Attributed
$3,423,536
Total exposure
2
Grants
2
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.5M · FY2022–25$2M$1.5M$1M$500K$0
'22
'23
'24
'25
Funding mix
By agency
NIH$3,423,536 · 2
By mechanism
R44$2,924,902 · 1
R42$498,634 · 1
Top collaborators
- Christopher Hulme3 shared
Most similar at Iluminos Therapeutics, Llc
Same institution · by research overlap
- Christopher Hulme$7,256,107
Others in their field
Other Rising Stars on “Alzheimer&Apos”
- Kjetil Bjornevik · Harvard University D/B/A Harvard School Of Public Health$3,280,861
- Yanling Wang · Rush University Medical Center$2,986,919
- William G Mantyh · University Of Minnesota$2,961,521
- Allison Mercedes Caban-Holt · University Of Miami School Of Medicine$2,611,182
- Brian Stephen Appleby · Cleveland Clinic Lerner Com-Cwru$2,482,260
- Noah Ray Johnson · University Of Colorado Denver$2,282,487
Research focus
Alzheimer&AposGenesCognitionEnzyme-Linked Immunosorbent AssayAge RelatedAlzheimer Like PathologyAmyloid PathologyAcuteBehavior3xtg-Ad MouseCanis FamiliarisChromosome 21ChronicClinical TrialsExhibitsCognitiveCognitive DeficitsCognitive DisabilityCommercializationDesignDisease PhenotypeBrainGene DosageGenetic
Grant awards (3)
Commercialization of Selective Dyrk1a Inhibitors for Down Syndrome$1,428,499
R44 · FY2025 · NS · contact PI
Commercialization of Selective Dyrk1a Inhibitors for Down Syndrome$1,496,403
R44 · FY2024 · NS · contact PI
Commercialization of Selective Dyrk1a Inhibitors for Down Syndrome$498,634
R42 · FY2022 · NS · contact PI